Outcomes of older patients with TP53-mutated myeloid neoplasms

This publication has 14 references indexed in Scilit:

• TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation
  Blood Advances, 2025
• Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
  Blood, 2024
• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
  Blood Cancer Journal, 2024
• Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
  Journal of Clinical Oncology, 2023
• Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
  Journal of Clinical Oncology, 2023
• TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
  Blood, 2023
• International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
  Blood, 2022
• Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
  American Journal of Hematology, 2022
• Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
  Journal of Clinical Oncology, 2021
• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
  New England Journal of Medicine, 2020